Switzerland-based Lonza Group AG (LZAGF.PK) said its first-quarter business performance was solid and in line with expectations. Looking ahead, the firm expects its second half of 2013 to be stronger than the first half of the year.
The chemical and pharmaceutical ingredients maker noted that in the first quarter, Specialty Ingredients market segment showed a good performance, while, Pharma&Biotech market segment had a slow start as anticipated.
Lonza added that strong cost controls and process improvements continue across the organization and head count reduction is in implementation phase.
Lonza also reiterated its 2013 EBIT guidance growth of about 10%.
For comments and feedback: editorial@rttnews.com